GeneDx Holdings Corp.
WGS Nasdaq
SEC CIK 1818331
Follow GeneDx Holdings Corp.
Weekly email: filings, results
Revenue, last quarter
$123.1M
+5.4% vs same quarter last year
Net income
−$12.3M
−61.5% vs same quarter last year
EPS, diluted
−$0.41
−51.9% vs same quarter last year
Operating cash flow
−$10.6M
−167.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $427.5M | −$21M |
| FY24 | $305.5M | −$52.3M |
| FY23 | $202.6M | −$175.8M |
| FY22 | $234.7M | −$549M |
| FY21 | $212.2M | −$245.4M |
| FY20 | $179.3M | −$241.3M |
| FY19 | $196.2M | −$29.7M |
| FY18 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 69.7% | −3.1% | −4.9% |
| FY24 | 63.6% | −7.6% | −17.1% |
| FY23 | 44.4% | −89.2% | −86.8% |
| FY22 | −11.4% | −284.5% | −233.9% |
| FY21 | −7.8% | −210.3% | −115.6% |
| FY20 | 2.2% | −134.9% | −134.6% |
| FY19 | 42.2% | −15.5% | −15.1% |
| FY18 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $14.3M |
| FY24 | −$34M |
| FY23 | −$185.4M |
| FY22 | −$326.3M |
| FY21 | −$199.8M |
| FY20 | −$117.2M |
| FY19 | −$30.7M |
| FY18 | - |
- GeneDx Holdings Corp.
- Healthcare median
Show the numbers
| Year | GeneDx Holdings Corp. | Healthcare median |
|---|---|---|
| FY25 | −4.9% | −30.6% |
| FY24 | −17.1% | −47% |
| FY23 | −86.8% | −58% |
| FY22 | −233.9% | −80.4% |
| FY21 | −115.6% | −71.9% |
| FY20 | −134.6% | −62.2% |
| FY19 | −15.1% | −46.3% |
| FY18 | - | −49.6% |